About

Reenal Gandhi is Global Business Development Director within Aptar Pharma’s Prescription division, where she is responsible for driving the assessment of potential new opportunities, with a specific focus on new technologies.

Until December 2020, she was Business Development Director at Bespak by Recipharm, where she was responsible for business development activities related to nasal devices and injectable devices such as autoinjectors and wearable injection systems.

Ms Gandhi has more than 15 years of experience in both the drug delivery device and pharma industries, developing and commercialising drug delivery solutions for biotech, vaccines and pharma. Throughout her career, she has been active in business development activities related to nasal devices and injectable devices such as prefilled syringes and autoinjectors. Her interest lies in developing combination products with drug delivery devices, balancing formulation, technology and commercial potential.

Contributions

NASAL

STEPS TO SUCCESS IN NOSE-TO-BRAIN DRUG DELIVERY

Reenal Gandhi and Gemma Budd consider the multiple hurdles associated with developing nasal drug delivery solutions, current understanding of the associated biology and the advantages of alternative device designs and state-of-the-art formulation practice.

More contributions

INJECTION

THE CHANGING FACE OF AUTOINJECTOR TECHNOLOGY

Reenal Gandhi discusses the advantages offered by liquefied gas as a power source for autoinjectors compared with conventional spring-based systems, as well as covering the benefits of using a platform model for drug delivery device development.